Dusan Perovic
Partner @ Two Sigma Ventures
New York, United States
Dusan Perovic is a Series B investor at Two Sigma Ventures in New York focused on Biotechnology and Life Science. Dusan directs Two Sigma Ventures investing efforts at the intersection of life science / healthcare and data science. He joined Two Sigma in 2007 to work on company growth strategy, and he has since helped the firm launch several new business units. Dusan also worked with research groups across the firm in discovering and evaluating new datasources, which are used in the firm’s investment algorithms.Before Two Sigma, he worked as a management consultant in healthcare/biotech, which he remains passionate about. He graduated from Princeton University with a BSE in Electrical Engineering (magna cum laude) and minors in German literature and dance.Dusan’s first foray into startups was both personal and professional: as a youth, he helped his parents launch their private-label soda business in then-Yugoslavia. Later, he attended an international boarding school in Norway, where he still likes to spend his summer vacations.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 18%
Last updated:
For AI agents: llms.txt
Industries Dusan Perovic invests in
Stages Dusan Perovic invests in
Countries Dusan Perovic invests in
Investment Focus
Industry
- Biotechnology 4 (36%)
- Life Science 3 (27%)
- Biopharma 2 (18%)
- Health Care 2 (18%)
- Medical 1 (9%)
Stage
- Series B 4 (36%)
- Series A 3 (27%)
- Venture - Series Unknown 2 (18%)
- Series C 1 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Freeform
|
Freeform is a 3D printing company offering metal 3D printing solutions for manufacturing companies. Freeform deploys software-defined, self-sufficient metal 3D printing factories around the world, bringing software scalability to physical production. Freeform's technology stack combines advanced sensing, real-time controls, and data-drivenlearning to produce digitally-verified, flawless parts at previously unheard-of speeds and costs. | $67M / Series B / Jan 07, 2026 | |
Gameto
|
Gameto is a biotechnology company whose mission is to redefine female reproductive health by developing therapies that improve lives.Women’s health is a vastly underserved therapeutic area. Most conditions have few treatment options, and those available often cause frequent complications and offer limited clinical benefit. Gameto aims to changethat.Gameto is committed to using cutting-edge scientific advances to deliver better solutions to patients. Using cellular engineering, they have developed a platform to produce female reproductive cell lines. They use proprietary combinations of transcription factors to reprogram hiPSCs into engineered ovarian and endometrium cell lines that mimic the functions of endogenous cells, producing and responding to all hormones. Their team of cellular engineers is using this platform to advance a portfolio of cellular therapeutics for female reproductive diseases. Gameto's first program, Fertilo, is a therapeutic for IVF and egg freezing, aiming to make the process shorter, safer and more effective. Additional applications of our platform include, an organoid of the female reproductive system, Deovo, and a cell-based therapeutic to ameliorate the health consequences of primary ovarian insufficiency and menopause, Ameno. | $44M / Series C / Aug 12, 2025 | |
Terray Therapeutics
|
Terray Therapeutics is a biotechnology company that integrates experimentation and computation to enhance small molecule drug discovery. The platform generates extensive, precise data through a rapid design-make-test-analyze cycle, allowing for efficient exploration of chemical space. By focusing on both wet lab science and AI, the companyaddresses complex therapeutic challenges across various targets. | $120M / Series B / Oct 17, 2024 | |
|
Gameto
|
Gameto is a biotechnology company whose mission is to redefine female reproductive health by developing therapies that improve lives.Women’s health is a vastly underserved therapeutic area. Most conditions have few treatment options, and those available often cause frequent complications and offer limited clinical benefit. Gameto aims to changethat.Gameto is committed to using cutting-edge scientific advances to deliver better solutions to patients. Using cellular engineering, they have developed a platform to produce female reproductive cell lines. They use proprietary combinations of transcription factors to reprogram hiPSCs into engineered ovarian and endometrium cell lines that mimic the functions of endogenous cells, producing and responding to all hormones. Their team of cellular engineers is using this platform to advance a portfolio of cellular therapeutics for female reproductive diseases. Gameto's first program, Fertilo, is a therapeutic for IVF and egg freezing, aiming to make the process shorter, safer and more effective. Additional applications of our platform include, an organoid of the female reproductive system, Deovo, and a cell-based therapeutic to ameliorate the health consequences of primary ovarian insufficiency and menopause, Ameno. | $33M / Series B / May 29, 2024 | |
|
Freeform
|
Freeform is a 3D printing company offering metal 3D printing solutions for manufacturing companies. Freeform deploys software-defined, self-sufficient metal 3D printing factories around the world, bringing software scalability to physical production. Freeform's technology stack combines advanced sensing, real-time controls, and data-drivenlearning to produce digitally-verified, flawless parts at previously unheard-of speeds and costs. | $45M / Venture - Series Unknown / Feb 01, 2023 | |
Hexagon Bio
|
Hexagon Bio is a data-driven biotech developing targeted small molecule therapeutics. Our proprietary platform combines data science and synthetic biology to discover and engineer drugs from DNA sequences. We are mining fungal genomes for inspiration for the next generation of targeted therapies for diseases with unmet needs. | $77.3M / Series B / Oct 11, 2022 | |
|
Terray Therapeutics
|
Terray Therapeutics is a biotechnology company that integrates experimentation and computation to enhance small molecule drug discovery. The platform generates extensive, precise data through a rapid design-make-test-analyze cycle, allowing for efficient exploration of chemical space. By focusing on both wet lab science and AI, the companyaddresses complex therapeutic challenges across various targets. | $60M / Series A / Feb 15, 2022 | |
|
Hexagon Bio
|
Hexagon Bio is a data-driven biotech developing targeted small molecule therapeutics. Our proprietary platform combines data science and synthetic biology to discover and engineer drugs from DNA sequences. We are mining fungal genomes for inspiration for the next generation of targeted therapies for diseases with unmet needs. | $61M / Series B / Sep 22, 2021 | |
|
Hexagon Bio
|
Hexagon Bio is a data-driven biotech developing targeted small molecule therapeutics. Our proprietary platform combines data science and synthetic biology to discover and engineer drugs from DNA sequences. We are mining fungal genomes for inspiration for the next generation of targeted therapies for diseases with unmet needs. | $61M / Venture - Series Unknown / Sep 22, 2021 | |
Xilis
|
Xilis is an oncology and precision health company that diagnoses cancer and finds the right treatment. The company uses “micro-organoids” to make thousands of 3D replicas of a patient’s tumor in about six days, which the company says can be used for testing for drug compatibility faster. It was founded in 2019 and is headquartered in Durham,North Carolina. | $70M / Series A / Jul 08, 2021 | |
| See all 11 investments → | |||
Co-Investors
About Two Sigma Ventures
Two Sigma Ventures is an early-stage venture capital fund based in New York City investing capital and expertise in entrepreneurs leveraging data and computing to create the future. In partnership with our parent company, Two Sigma Investments, we provide entrepreneurs access to a proprietary network of experts and startup resources to give them acompetitive edge.
Two Sigma Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Colin Beirne
Partner
|
|||
David Joerg
Managing Director
|
|||
|
Dusan Perovic
Partner
|
|||
Edward Schmidt
Venture Partner
|
|||
Frances Schwiep
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Dusan Perovic invest in?
Dusan Perovic invests primarily in Biotechnology, Life Science and Biopharma startups, most often at Series B and Series A stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Dusan Perovic last invest?
The most recent investment recorded for Dusan Perovic closed in Jan 2026. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
